| Literature DB >> 28367191 |
Adil Can Gungen1, Belma Gungen2.
Abstract
BACKGROUND ANDEntities:
Keywords: Asthma; Headache; Migraine
Year: 2017 PMID: 28367191 PMCID: PMC5368299 DOI: 10.12669/pjms.331.11720
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Demographic and clinical characteristics, laboratory and respiratory test function results.
| Asthma (n=93) | Controls (n=58) | P value | |
|---|---|---|---|
| Sex (F/M) | (62 /31) | (41/17) | 0.295 |
| Age | 48.48 ± 11.6 | 46.3 ±9.1 | 0.063 |
| Hemoglobin(gr/dl) | 13.4 ±1.12 | 13.4±1.1 | 0.751 |
| IGE (IU/ml) | 182.3±263 | - | |
| Age at onset | 41.2±13.2 | - | |
| Disease duration | 7.15±7.42 | - | |
| Number of attacks (year) | 2.1±1.4 | - | |
| ACT | 17.5±5.2 | - | |
| FVC (%) | 85.01±17.7 | - | |
| FEV1 (%) | 77.2±19.1 | - | |
| FEV1/FVC | 77±7.9 | - | |
| PEF (%) | 77.4±22.5 | - |
ACT, Asthma Control Test™; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow; IgE, immunoglobulin E.
Comparison of headache, headache types, and emotional state between patients with asthma and control subjects.
| Asthma patients (n=93) | Control subjects (n=58) | P value | |
|---|---|---|---|
| N (%) | N (%) | ||
| Presence of headache | 58(62.4) | 19(32.8) | 0.001 |
| Migraine-type headache | 19(20.3) | 5(8.6) | 0.04 |
| Tension-type headache | 32(34.4) | 11 (19) | 0.03 |
| Other types of headache | 7(7.5) | 3(5.2) | 0.41 |
| Depression | 36(38.7) | 11(19) | 0.002 |
| Anxiety | 36(38.7) | 9(15.5) | 0.008 |
| BAI score | 13.3±7.9 | 8.3± 5.3 | 0.002 |
| BDI score | 7.6±5.6 | 5.7 ±3.3 | 0.004 |
BAI: Beck Anxiety Inventory,
BDI: Beck Depression Inventory.
Correlation between headache and age, sex, ACT, inhaled steroid use, β2 agonist use, IgE, FVC, FEV1, FEV1/FVC (%) and PEF in patients with asthma.
| N=93 | Headache present | Headache absent | P value |
|---|---|---|---|
| Sex (F/M) | 41 / 17 | 21 / 14 | 0.054 |
| Age | 48.7±11.4 | 48.02±12.2 | 0.560 |
| Disease duration | 7.2±8 | 6.9±6.3 | 0.324 |
| Age at onset (years) | 41.3±13.11 | 41±13.5 | 0.649 |
| ACT | 17.2±5.3 | 18.05±5.1 | 0.817 |
| FVC (%) | 82.6±16.3 | 88.9±19.4 | 0.161 |
| FEV1 (%) | 76.4±18.6 | 78.8±20.4 | 0.608 |
| FEV1/FVC (%) | 76.8±7.4 | 77.2±8.7 | 0.579 |
| PEF (%) | 76.3±23.1 | 79.1±21.7 | 0.703 |
| IGE | 181.8±284 | 183±248.6 | 0.873 |
| Beck depression score | 13.3±7.6 | 5.7±4.4 | 0.036 |
| Beck anxiety score | 8.7±6.2 | 11.4±8.5 | 0.358 |
| Inhale steroid use | 39 (67.2) | 28 (80) | 0.138 |
| β2 agonist use | 53 (91.3) | 32 (91.4) | 0.652 |
ACT, Asthma Control Test™; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow; IgE, immunoglobulin E.
Correlation between migraine and age, sex, ACT, inhaled steroid use, β2 agonist use, presence of allergies, IgE, FVC, FEV1, FEV1/FVC (%) and PEF in patients with asthma.
| N=93 | Migraine present | Migraine absent | P value |
|---|---|---|---|
| Sex (F/M) | 11/8 | 51/23 | 0.259 |
| Age | 41.1±11.6 | 50.3±10.9 | 0.03 |
| Disease duration | 8.8±9.17 | 7.2±6.8 | 0.359 |
| Frequency of attacks | 2.4±2.2 | 2.1±1.24 | 0.920 |
| ACT | 16.7 ±5.1 | 17.7±5.3 | 0.44 |
| FVC (%) | 76.9±17.2 | 87.08±17.3 | 0.011 |
| FEV1 (%) | 67.2±18.6 | 79.8±18.5 | 0.015 |
| FEV1/FVC (%) | 73.7 ±7.6 | 77.8±7.8 | 0.037 |
| PEF (%) | 73.3±22.8 | 78.4±7.8 | 0.511 |
| IGE | 236±380.5 | 168.5±225.2 | 0.289 |
| Inhale steroid use | 10 (52.6) | 57 (77.02) | 0.037 |
| β2 agonist use | 16 (84.2) | 69 (93.2) | 0.205 |
| Presence of allergies | 14 (73.6) | 21 (28.3) | 0.001 |
ACT, Asthma Control Test™; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; PEF, peak expiratory flow; IgE, immunoglobulin E.
Multivariate logistic regression model for Migraine.
| β | S.E. of β | p values | OR (95% C.I. for OR) | |
|---|---|---|---|---|
| Age | 0.106 | 0.032 | 0.001 | 1.112 (1.044-1.185) |
| Presence of allergies | 1.877 | 0.701 | 0.007 | 6.533 (1.653-25.814) |
| FVC (%) | 0.104 | 0.062 | 0.093 | 1.11 (0.983-1.254) |
| FEV1 (%) | -0.068 | 0.061 | 0.265 | 0.934 (0.828-1.053) |
| FEV1/FVC (%) | 0.131 | 0.069 | 0.05 | 1.140 (0.996-1.304) |
| Inhale steroid use | -0.740 | 0.720 | 0.304 | 0.477(0.116-1.958) |
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second.